FBR Adds Senior Analyst to Healthcare Practice
February 17 2015 - 12:30PM
FBR & Co. (Nasdaq:FBRC) (FBR), a leading investment bank
serving the middle market, announced the hiring of Christopher S.
James, M.D., as Senior Vice President, Senior Research Analyst in
its Equity Research Department. Dr. James will be based in New York
and will focus on the biotech sector.
"Chris's operational experience, his tenure as a Wall Street
analyst, and his medical background give him a unique perspective
which will serve our clients well," said David M. Hilal, Senior
Managing Director and Director of Research at FBR. "Adding
Chris's coverage to our existing platform will provide additional
breadth and depth to our healthcare franchise as we continue to
deliver quality, value-add research through our proprietary
framework - The Debate TM."
Since graduating from the Yale School of Medicine 14 years ago,
Dr. James has held various product development positions in biotech
companies and has served as an equity healthcare analyst on both
the buy and sellside. He is a graduate of Cornell University
and holds an M.D. from Yale University. After medical school, he
trained in neurosurgery at Weill Cornell-New York Presbyterian
Hospital.
FBR & Co. (Nasdaq:FBRC) provides investment banking, merger
and acquisition advisory, institutional brokerage, and research
services through its subsidiary FBR Capital Markets & Co. FBR
focuses capital and financial expertise on the following industry
sectors: consumer; diversified industrials; energy & natural
resources; financial institutions; healthcare; insurance; real
estate; and technology, media & telecom. FBR is headquartered
in the Washington, D.C. metropolitan area with offices throughout
the United States. For more information, please visit
www.fbr.com.
Statements in this release concerning future performance,
developments, events, market forecasts, revenues, expenses,
earnings, run rates and any other guidance on present or future
periods constitute forward-looking statements. These
forward-looking statements are subject to a number of factors,
risks and uncertainties that might cause actual results to differ
materially from stated expectations or current circumstances. These
factors include, but are not limited to, the effect of demand for
public and private securities offerings, activity in the secondary
securities markets, interest rates, the risks associated with
merchant banking investments, the realization of gains and losses
on principal investments, available technologies, competition for
business and personnel, and general economic, political and market
conditions. For a discussion of these and other risks and important
factors that could affect FBR's future results and financial
condition, see "Risk Factors" in Part I, Item 1A and "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" in Part II, Item 7 of the Company's Annual Report on
Form 10-K for the fiscal year ended December 31, 2013; and other
items throughout the Company's Form 10-K, Quarterly Reports on Form
10-Q, and Current Reports on Form 8-K.
CONTACT: Investors:
Bradley J. Wright at 703.312.9678 or bwright@fbr.com
Media:
Shannon Hawkins at 703.469.1190 or shawkins@fbr.com
Fbr & (NASDAQ:FBRC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Fbr & (NASDAQ:FBRC)
Historical Stock Chart
From Jul 2023 to Jul 2024